Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure

International Journal of Molecular Medicine

Volumn 34, Issue 3, 2014, Pages 756-764

  Pang, Hui ^a   Han, Bing ^a   Yu, Tao ^a   Zong, Zhenkun ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Heart failure; Hypertension; Pyroglutamylated apelin 13

Indexed keywords

APELIN; APELIN RECEPTOR; CYCLIC AMP; GLUCOSE; PYROGLUTAMYLATED APELIN 13; UNCLASSIFIED DRUG; APELIN-13 PEPTIDE; APLNR PROTEIN, RAT; CARDIOTONIC AGENT; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG TARGETING; ECHOCARDIOGRAPHY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART RATE; HEMODYNAMIC PARAMETERS; HISTOLOGY; HYPERTENSION; INFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; CELL SEPARATION; COMPLICATION; DRUG EFFECTS; ECHOGRAPHY; ENZYMOLOGY; FIBROSIS; HEART; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; CARDIOTONIC AGENTS; CELL SEPARATION; CYCLIC AMP; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; HEART; HEART FAILURE; HEMODYNAMICS; HYPERTENSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84905026195     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1829     Document Type: Article

References (29)

1. Tatemoto K, Hosoya M, Habata Y, et al: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476, 1998. (Pubitemid 28505047)
2. Maguire JJ, Kleinz MJ, Pitkin SL, et al: [Pyr1] apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54: 598-604, 2009.
3. Chun HJ, Ali ZA, Kojima Y, et al: Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 118: 3343-3354, 2008.
4. Iturrioz X, El Messari S, De Mota N, et al: Functional dissociation between apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. Arch Mal Coeur Vaiss 100: 704-708, 2007. (Pubitemid 47518703)
5. Rastaldo R, Cappello S, Folino A, et al: Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool? Antioxid Redox Signal 14: 909-922, 2011.
6. Iturrioz X, Alvear-Perez R, De Mota N, et al: Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 24: 1506-1517, 2010.
7. Shan PF, Lu Y, Cui RR, et al: Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PLoS One 6: e17938, 2011.
8. Roberts EM, Newson MJ, Pope GR, et al: Abnormal fluid homeostasis in apelin receptor knockout mice. J Endocrinol 202: 453-462, 2009.
9. Zhang Z, Yu B and Tao GZ: Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J 122: 2360-2365, 2009.
10. Foussal C, Lairez O, Calise D, et al: Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett 584: 2363-2370, 2010.
11. Przewlocka-Kosmala M, Kotwica T, Mysiak A, et al: Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 29: 971-979, 2011.
12. Khalili A, Khosravi MB and Nekooeian AA: The effects of aqueous extract of vaccinium arctostaphylos leaves on blood pressure in renal hypertensive rats. Iran Red Crescent Med J 13: 123-127, 2011.
13. Zhou ZY, Yang ZH, Wang XH, et al: Increased expression of insulin-like growth factor-binding protein-3 is implicated in erectile dysfunction in two-kidney one-clip hypertensive rats after propranolol treatment. Asian J Androl 13: 851-855, 2011.
14. Lewis CJ, Gong H, Brown MJ, et al: Overexpression of β1- adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' β4-adrenoceptor pharmacology. Br J Pharmacol 141: 813-824, 2004. (Pubitemid 38446182)
15. Glasser SP, Judd S, Basile J, et al: Prehypertension, racial prevalence and its association with risk factors: analysis of the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Hypertens 24: 194-199, 2011.
16. Shahbaz AU, Sun Y, Bhattacharya SK, et al: Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens 28 (Suppl 1): S25-S32, 2010.
17. Chen MM, Ashley EA, Deng DX, et al: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108: 1432-1439, 2003. (Pubitemid 37176447)
18. Koguchi W, Kobayashi N, Takeshima H, et al: Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 76: 137-144, 2012.
19. Japp AG, Cruden NL, Barnes G, et al: Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121: 1818-1827, 2010.
20. Simpkin JC, Yellon DM, Davidson SM, et al: Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 102: 518-528, 2007. (Pubitemid 47578397)
21. Langelaan DN, Reddy T, Banks AW, et al: Structural features of the apelin receptor N-terminal tail and first transmembrane segment implicated in ligand binding and receptor trafficking. Biochim Biophys Acta 1828: 1471-1483, 2013.
22. Dang VC and Christie MJ: Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. Br J Pharmacol 165: 1704-1716, 2012.
23. Yoshizawa T, Sakurai T, Kamiyoshi A, et al: Novel regulation of cardiac metabolism and homeostasis by the adrenomedullin-receptor activity-modifying protein 2 system. Hypertension 61: 341-351, 2013.
24. Shaul YD and Seger R: The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773: 1213-1226, 2007. (Pubitemid 47125968)
25. Hausenloy DJ and Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448-460, 2004. (Pubitemid 38210151)
26. Rattazzi M, Bertacco E, Puato M, et al: Hypertension and vascular calcification: a vicious cycle? J Hypertens 30: 1885-1893, 2012.
27. Distefano G and Sciacca P: Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure. Ital J Pediatr 38: 41, 2012.
28. Moser E, Kargl J, Whistler JL, et al: G protein-coupled receptor-associated sorting protein 1 regulates the postendocytic sorting of seven-transmembrane-spanning G protein-coupled receptors. Pharmacology 86: 22-29, 2010.
29. Pang H and Zhang P: Detection of the level of apelin during remodeling in hypertensive heart failure rats. Chin J Clinicians 6: 64-67, 2012.